Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

89,137 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Benefit, recurrence pattern, and toxicity to adjuvant anti-PD-1 monotherapy varies by ethnicity and melanoma subtype: An international multicenter cohort study.
Bai X, Lawless AR, Czapla JA, Gerstberger SC, Park BC, Jung S, Johnson R, Yamazaki N, Ogata D, Umeda Y, Li C, Guo J, Flaherty KT, Nakamura Y, Namikawa K, Long GV, Menzies AM, Johnson DB, Sullivan RJ, Boland GM, Si L. Bai X, et al. Among authors: li c. JAAD Int. 2024 Jan 19;15:105-114. doi: 10.1016/j.jdin.2023.11.014. eCollection 2024 Jun. JAAD Int. 2024. PMID: 38500872 Free PMC article.
Overall Survival of Patients With Unresectable or Metastatic BRAF V600-Mutant Acral/Cutaneous Melanoma Administered Dabrafenib Plus Trametinib: Long-Term Follow-Up of a Multicenter, Single-Arm Phase IIa Trial.
Mao L, Ding Y, Bai X, Sheng X, Dai J, Chi Z, Cui C, Kong Y, Fan Y, Xu Y, Wang X, Tang B, Lian B, Yan X, Li S, Zhou L, Wei X, Li C, Guo J, Zhang X, Si L. Mao L, et al. Among authors: li s, li c. Front Oncol. 2021 Aug 24;11:720044. doi: 10.3389/fonc.2021.720044. eCollection 2021. Front Oncol. 2021. PMID: 34504796 Free PMC article.
Molecular underpinnings of exceptional response in primary malignant melanoma of the esophagus to anti-PD-1 monotherapy.
Dai J, Bai X, Gao X, Tang L, Chen Y, Sun L, Wei X, Li C, Qi Z, Kong Y, Cui C, Chi Z, Sheng X, Xu Z, Lian B, Li S, Yan X, Tang B, Zhou L, Wang X, Xia X, Guo J, Mao L, Si L. Dai J, et al. Among authors: li c, li s. J Immunother Cancer. 2023 Jan;11(1):e005937. doi: 10.1136/jitc-2022-005937. J Immunother Cancer. 2023. PMID: 36593066 Free PMC article.
Camrelizumab Plus Apatinib and Temozolomide as First-Line Treatment in Patients With Advanced Acral Melanoma: The CAP 03 Phase 2 Nonrandomized Clinical Trial.
Mao L, Lian B, Li C, Bai X, Zhou L, Cui C, Chi Z, Sheng X, Wang X, Tang B, Yan X, Li S, Kong Y, Dai J, Wei X, Li J, Duan R, Xu H, Wu X, Yang Y, Cheng F, Zhang C, Xia F, Pang Z, Guo J, Si L. Mao L, et al. Among authors: li c, li s, li j. JAMA Oncol. 2023 Aug 1;9(8):1099-1107. doi: 10.1001/jamaoncol.2023.1363. JAMA Oncol. 2023. PMID: 37261804 Free PMC article. Clinical Trial.
A nomogram incorporating Ki67 to predict survival of acral melanoma.
Du Y, Li C, Mao L, Wei X, Bai X, Chi Z, Cui C, Sheng X, Lian B, Tang B, Wang X, Yan X, Li S, Zhou L, Guo J, Si L. Du Y, et al. Among authors: li c, li s. J Cancer Res Clin Oncol. 2023 Nov;149(14):13077-13085. doi: 10.1007/s00432-023-05127-w. Epub 2023 Jul 20. J Cancer Res Clin Oncol. 2023. PMID: 37470854 Free PMC article.
89,137 results
You have reached the last available page of results. Please see the User Guide for more information.